The 2022 Tandem Meetings | Outcomes of alloHSCT in TP53-mutated AML and MDS
Muhammad Umair Mushtaq
• 25 Apr 2022
Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, discusses the role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). According to Dr Mushtaq, although the outcomes of patients with AML and MDS remain very poor after alloHSCT, it still provides a survival benefit in this difficult-to-treat patient population. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
